Oral Methods of Microbiota Manipulation for Depression Symptoms: A Systematic Review: Méthodes orales de manipulation du microbiote pour traiter les symptômes de dépression : Une revue systématique.

Can J PsychiatryNov 27, 2025 (epub)
Clinical ResearchPsychiatryOpen access

Anna Oprea, Joe Steinman, Grace Huang et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined completed parallel-arm randomised controlled trials of oral microbiota manipulation and depressive symptoms in adults not taking antidepressants. It included 66 trials; 34 reported significant intervention–control differences in depressive symptoms. Interventions included probiotics, prebiotics, synbiotics and oral faecal microbiota transplantation, with substantial variation in study design, intervention composition, administration and outcome measures. This heterogeneity prevented statistical synthesis or meta-analysis, and the authors concluded that the evidence does not support concrete conclusions about whether these approaches are viable alternatives for adults experiencing depressive symptoms.

Key findings

  • Of 66 included randomised trials, 34 reported significant differences in depressive symptoms between intervention and control groups.
  • Interventions comprised probiotics in 54 trials, prebiotics in seven, synbiotics in eight and oral faecal microbiota transplantation in two.
  • Variation in interventions, measures and outcomes precluded statistical synthesis or meta-analysis.

Why it matters

Interest in microbiota-based approaches reflects the limitations and acceptability concerns associated with existing depression treatments. This review shows that although many trials have reported differences in depressive symptoms, their varied methods and outcomes make the overall evidence difficult to interpret. Standardised study design and reporting would help determine whether oral microbiota manipulation has a reliable role in depression care.

What to keep in mind

The included trials were highly heterogeneous, preventing meta-analysis and firm conclusions about efficacy.

Source

Published in Can J Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.